Legend Biotech (LEGN) Is Up 7.3% After CARVYKTI Reaches Profitability And 10,000 Patients Treated

Simply Wall St.03-13 10:31

In March 2026, Legend Biotech reported fourth-quarter 2025 revenue of US$306.3 million, up from US$186.5 million a year earlier, with an adjusted profit of US$0.01 per share but a GAAP net loss of US$...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2619154022?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-03-13 10:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619154022","market":"sg","top_or_hot":-1,"title":"Legend Biotech (LEGN) Is Up 7.3% After CARVYKTI Reaches Profitability And 10,000 Patients Treated","media":"Simply Wall St.","content":"<div>\n<p>In March 2026, Legend Biotech reported fourth-quarter 2025 revenue of US$306.3 million, up from US$186.5 million a year earlier, with an adjusted profit of US$0.01 per share but a GAAP net loss of US$...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/legend-biotech-legn-is-up-73-after-carvykti-reaches-profitab\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Legend Biotech (LEGN) Is Up 7.3% After CARVYKTI Reaches Profitability And 10,000 Patients Treated</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLegend Biotech (LEGN) Is Up 7.3% After CARVYKTI Reaches Profitability And 10,000 Patients Treated\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-13 10:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/legend-biotech-legn-is-up-73-after-carvykti-reaches-profitab><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In March 2026, Legend Biotech reported fourth-quarter 2025 revenue of US$306.3 million, up from US$186.5 million a year earlier, with an adjusted profit of US$0.01 per share but a GAAP net loss of US$...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/legend-biotech-legn-is-up-73-after-carvykti-reaches-profitab\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4581","symbol_name":"高盛持仓","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/legend-biotech-legn-is-up-73-after-carvykti-reaches-profitab","article_id":"2619154022","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/legend-biotech-legn-is-up-73-after-carvykti-reaches-profitab","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2619154022","pubTimestamp":1773369104,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In March 2026, Legend Biotech reported fourth-quarter 2025 revenue of US$306.3 million, up from US$186.5 million a year earlier, with an adjusted profit of US$0.01 per share but a GAAP net loss of US$30.9 million for the quarter and US$296.8 million for the full year on revenue of US$1.03 billion.\nThe company’s CARVYKTI franchise reached more than 10,000 treated patients, achieved product-level profitability in 2025, and expanded to 294 treatment sites across 14 markets while scaling...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4581":"高盛持仓","BK4543":"AI","AI":"C3.ai, Inc.","BK4023":"应用软件","BK4139":"生物科技","BK4551":"寇图资本持仓","BK4587":"ChatGPT概念","LEGN":"传奇生物","BK4505":"高瓴资本持仓","BK4585":"ETF&股票定投概念","BK4588":"碎股","BK4528":"SaaS概念","XBI":"SPDR S&P Biotech ETF","AIYY":"YIELDMAX AI OPTION INCOME STRATEGY ETF"},"translate_title":"CARVYKTI实现盈利并治疗10,000名患者后，传奇生物(LEGN)股价上涨7.3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XBI":1.5,"AIYY":0.6,"LEGN":1.5,"AI":0.81},"content_text":"In March 2026, Legend Biotech reported fourth-quarter 2025 revenue of US$306.3 million, up from US$186.5 million a year earlier, with an adjusted profit of US$0.01 per share but a GAAP net loss of US$30.9 million for the quarter and US$296.8 million for the full year on revenue of US$1.03 billion. The company’s CARVYKTI franchise reached more than 10,000 treated patients, achieved product-level profitability in 2025, and expanded to 294 treatment sites across 14 markets while scaling manufacturing capacity toward 20,000 doses annually and advancing an early-stage cell therapy pipeline. With CARVYKTI’s profitability and manufacturing ramp now clearer, we’ll examine how this progress reshapes Legend Biotech’s investment narrative. The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.AdvertisementLegend Biotech Investment Narrative RecapTo own Legend Biotech, you need to believe CARVYKTI can sustain its commercial traction long enough for the broader cell therapy pipeline to matter, while the company moves closer to consistent profitability. The latest results clarify that CARVYKTI is now product profitable and scaling, which supports the near term catalyst around higher utilization and site expansion. However, the continued GAAP net loss underlines the key risk that company wide profitability and diversification beyond a single asset remain unresolved. Among the recent announcements, management’s confirmation that CARVYKTI net trade sales reached about US$1.9 billion in 2025 and that the franchise is profitable feels most relevant. It ties directly to the current earnings release and to the core catalyst: whether Legend can convert strong CARVYKTI demand, expanded to 294 global sites, into durable cash generation while still funding its early stage in vivo and allogeneic programs without materially extending the path to overall profitability. Yet even with CARVYKTI’s franchise profitability, investors still need to think carefully about how concentrated the business is and whether... Read the full narrative on Legend Biotech (it's free!)Legend Biotech's narrative projects $2.3 billion revenue and $632.7 million earnings by 2028. This requires 42.3% yearly revenue growth and about a $958 million earnings increase from -$325.3 million today.Uncover how Legend Biotech's forecasts yield a $58.70 fair value, a 208% upside to its current price.Exploring Other PerspectivesLEGN 1-Year Stock Price Chart Some of the lowest estimate analysts were already cautious, assuming about US$2.1 billion revenue and US$254 million earnings by 2028, which contrasts sharply with the current CARVYKTI progress and shows how differently you and other investors might weigh concentration risk versus growth potential once this latest update is fully reflected.Explore 6 other fair value estimates on Legend Biotech - why the stock might be worth just $21.00!Reach Your Own ConclusionDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Legend Biotech research is our analysis highlighting 3 key rewards that could impact your investment decision.Our free Legend Biotech research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Legend Biotech's overall financial health at a glance.Curious About Other Options?Every day counts. These free picks are already gaining attention. See them before the crowd does:Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.Find 48 companies with promising cash flow potential yet trading below their fair value.Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2619154022","isCrawlerRequest":true}